Biopredic International is a biotechnology company specializing in the development and manufacturing of in vitro biological products and services for drug discovery and development, toxicology studies, and dermo-cosmetics. They are renowned for their high-quality human and animal primary hepatocytes, liver subcellular fractions (microsomes, S9), and other hepatic reagents. Biopredic also offers a range of services, including ADME (Absorption, Distribution, Metabolism, Excretion) and toxicology testing. Following its merger with KaLy-Cell in 2023, the group aims to be a European leader in non-animal testing methods for assessing drug and chemical safety.
Serves as a primary center for research and development, product manufacturing (especially hepatic cells and reagents), strategic operations, and administration for Biopredic's global activities.
State-of-the-art cell culture laboratories, cryopreservation facilities, biobanking, and advanced bioanalytical equipment necessary for producing high-quality biological products and conducting complex in vitro studies.
A scientifically-driven and innovative environment, fostering collaboration among researchers, technicians, and commercial teams. There is an emphasis on precision, quality, and contributing to advancements in drug development and safety testing methodologies.
Key hub for Biopredic's pioneering work in in vitro toxicology and ADME studies. Post-merger with KaLy-Cell, it forms a critical part of a leading European entity in the sector, contributing to innovation in non-animal testing methods and alternatives to animal experimentation.
Biopredic International serves a global clientele, including pharmaceutical companies, contract research organizations (CROs), biotech firms, cosmetic industries, and academic research institutions worldwide. This global reach is supported through its main operational sites in France, a dedicated US office in Cambridge, MA, and an extensive network of international distributors. This structure ensures efficient delivery and support for its specialized in vitro products and services across North America, Europe, Asia, and other key markets.
Parc d'Affaires de la Bretèche, Bâtiment A4
Saint-Grégoire
Brittany (Ille-et-Vilaine)
France
Address: Parc d'Innovation, Rue Tobias Stimmer, Bâtiment C, 67400 Plobsheim, France
Strengthens the group's R&D and production capabilities in Eastern France, complementing the Rennes site and expanding its European footprint for advanced in vitro solutions.
Address: Biopredic International Inc., One Broadway, 14th Floor, Cambridge, MA 02142, USA
Manages business development, client relations, and logistical operations for the North American market, a key region for drug discovery and development.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Biopredic International' leadership includes:
Biopredic International has been backed by several prominent investors over the years, including:
Following the strategic merger between Biopredic International and KaLy-Cell in October 2023, key leadership roles were established for the new group. Vincent Géli, formerly CEO of KaLy-Cell, was appointed CEO of the combined entity. Christophe Chesné, founder and former CEO of Biopredic International, transitioned to the role of Chairman of the new group.
Discover the tools Biopredic International uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Biopredic International primarily uses the domain biopredic.com for its email communications. Common corporate email patterns are typically employed.
[first_initial][last]@biopredic.com
Format
vjeli@biopredic.com
Example
85%
Success rate
Business Wire • May 9, 2024
Biopredic International and Accelevia have formed a strategic partnership to offer integrated drug development solutions. This collaboration aims to combine Biopredic's expertise in in vitro ADME-Tox models with Accelevia's capabilities in accelerating clinical development, providing clients with a more streamlined path from preclinical research to clinical trials....more
PR Newswire • October 18, 2023
Biopredic International and KaLy-Cell merged to form a leading European group in ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicology) and in vitro toxicology. The merger, supported by investors Korys and Archimed, aims to enhance R&D capabilities, expand product offerings, and strengthen market presence. Vincent Géli was appointed CEO of the new group, with Christophe Chesné as Chairman....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Biopredic International, are just a search away.